Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
August 12, 2021 08:05 ET
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
August 10, 2021 09:00 ET
|
Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
August 09, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
July 13, 2021 08:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress
July 06, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine to Present at 2021 Jefferies Healthcare Conference
May 26, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
May 19, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results
May 13, 2021 16:05 ET
|
Metacrine, Inc.
• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the...
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
February 24, 2021 10:00 ET
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...